CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10,471 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01671007
NCT01671007N/ACompleted

GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase II/III - EU/EEA Member States)

Boehringer Ingelheim·observational·Posted Aug 23, 2012·Updated Dec 31, 2020

In Brief

An observational study for Stroke and Atrial Fibrillation. Completed, enrolled 10,471 participants across 522 sites in 22 countries.

Detailed Summary

In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into two protocol numbers: 1160.129 for non-EU (European Union) and non-EEA (European Economic Area) countries, and 1160.136 for EU and EEA countries. The total number of patients enrolled in both protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Belgium, Bulgaria, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Ireland, Italy, Latvia, Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 23, 2012
Enrollment StartAug 22, 2012
Primary CompletionDec 13, 2019
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 13.9 years ago